Vitaliy Vladimirovich Omelyanovskiy

Vitaliy Vladimirovich Omelyanovskiy

Auto-generated profile, based on publicly available information

Vitaliy Vladimirovich Omelyanovskiy

Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
SBSergey Boytsov
Sergey Boytsov
VOV. V. Omelyanovskiy
V. V. Omelyanovskiy
AKA. V. Kontsevaya
A. V. Kontsevaya
MLM. M. Loukianov
M. M. Loukianov
EDE. V. Derkach
E. V. Derkach
Heart failure (HF) significantly worsens the patient quality of life and leads to the disability of their significant part, as well as increases the risk of death, which in turn causes economic damage.Aim. To assess the annual socio-economic impact of HF in Russia.Material and methods. To assess the socio-economic impact of HF, a model was developed, which assessed the number of HF patients seeking medical care (data from the epidemiological studies), the number of those with disabilities and the mortality rate among them. We also evaluated the costs of drug therapy (data from the government procurement reports) and hospitalization (data from the compulsory health insurance tariffs), social benefits due to disability, and death impact on the gross domestic product. Data on the prescription rate, hospitalizations and mortality was obtained from Russian registries of patients with cardiovascular diseases. Using the foreign study, the costs of family caregiving were also calculated.Results. According to modeling data, there are 7,1 million people with HF seeking medical care in Russia. In this case, the annual economic impact of HF in the context of government spending, is RUB 81,86 billion, including medical costs of RUB 18,6 billion, direct nonmedical costs of RUB 47,1 billion, and indirect costs of RUB 16,2 billion. The impact of family caregiving is RUB 72,4 billion. In the structure of medical expenses, 73,6% is hospitalization costs, while the main costs of drug therapy are borne by patients, since only a part of them (19,6%) receive the necessary medications within assistance programs. In patients with HF with reduced ejection fraction, medical costs are 56% higher than in patients with HF with preserved ejection fraction.Conclusion. HF causes significant economic burden to the state. Improving the healthcare system for this category of patients, including preferential drug provision, will reduce HF-related mortality, the healthcare system costs and, accordingly, reduce the economic impact on the state and society.

10 January 2016 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
IDIvan Ivanovich Dedov
Ivan Ivanovich Dedov
VOVitaliy Vladimirovich Omelyanovskiy
Vitaliy Vladimirovich Omelyanovskiy
MSMarina Shestakova
Marina Shestakova
MAMaria Vladimirovna Avksentieva
Maria Vladimirovna Avksentieva
VIViktoria Igorevna Ignatieva
Viktoria Igorevna Ignatieva
Objective.To estimate annual expenditures attributed to diabetes mellitus (DM) per patient in Russia based on data from epidemiologic studies and to analyse DM cost drivers.Methods.The expenditures per diabetic patient were calculated as the sum of medical costs (outpatient and emergency room visits, inpatient care and medications provided during outpatient care), payments for sick leaves, disability pensions and gross domestic production (GDP) losses due to temporary disability (indirect costs). All data on resource consumption and productivity losses were derived from the dataset for Russia, collected from the point of view of a multicentre international study on the practice of DM treatment. Medication costs were based on registered governmental price lists (list of vital and essential drugs). Medical care costs were estimated using the approved public health care reimbursement rates. Disability payments were calculated on the basis of data published by the Russian Pension Fund and Social Security Fund. GDP losses were assessed using federal statistics.Results.The mean total annual costs per patient with DM type 1 (T1) were 81.1 thousand Russian rubles (RUR) and those per patient with DM type 2 (T2) were 70.8 thousand RUR. Although most patients with DMT2 were 60 years, approximately 25% of costs were nonmedical and caused by productivity losses; for patients with DM type 1(T1), this proportion was 35%. The medical cost structure differed depending on the type of diabetes. In T1, the main component was attributed to DM treatment; in DMT2, almost half of medical costs were due to DM complications. Medication costs accounted for 69% and inpatient care accounted for only 22% of medical costs in DMT1. For DMT2, the proportion spent on inpatient care (43%) was almost equal to medication costs (46%). Mean expenditures per patient with DM complications were higher; in the case of DMT2, the presence of complications increased the costs by 3 times. Mean medical costs were higher for patients not reaching the target level of Hb1Ac than those reaching it, despite age or the presence of complications. The results of regression analysis showed that the strongest predictors of costs growth were the number of admissions, presence of complications and insulin treatment. It was also demonstrated that the mean medical cost per patient with uncomplicated DM T2 on insulin therapy was 38.5 thousand RUR, which was comparable to the cost per patient with complications, receiving other glucose-lowering treatment (37.0 thousand RUR).Conclusion.Costs for patients with DM complications are considerably higher than those for patients without complications. Therefore, the key point in controlling the growth of the DM economic burden is to minimise and/or prevent the development of DM complications, which could be achieved by timely DM diagnosis and appropriate glucose-lowering therapy.

7 February 2021 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
TTT. S. Teptsova
T. S. Teptsova
NMN. Z. Musina
N. Z. Musina
VOV. V. Omelyanovsky
V. V. Omelyanovsky
Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system

7 February 2021 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
NMN. Z. Musina
N. Z. Musina
VOV. V. Omelyanovskiy
V. V. Omelyanovskiy
RGR. V. Gostischev
R. V. Gostischev
OSO. A. Sukhorukikh
O. A. Sukhorukikh
VFV. K. Fedyaeva
V. K. Fedyaeva
DSD. G. Shchurov
D. G. Shchurov
Concept of value-based healthcare

1 January 2020 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
PDF file
IZI.A. Zheleznyakova
I.A. Zheleznyakova
TKT.A. Khelisupali
T.A. Khelisupali
VOV.V. Omelyanovskiy
V.V. Omelyanovskiy
STS.N. Tishkina
S.N. Tishkina

23 April 2024 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
ERE.I. Rumyantseva
E.I. Rumyantseva
IZI.A. Zheleznyakova
I.A. Zheleznyakova
OPO.S. Plakhotnik
O.S. Plakhotnik
FNF.S. Nikitin
F.S. Nikitin
TVT.S. Vakhrusheva
T.S. Vakhrusheva
VOV.V. Omelyanovskiy
V.V. Omelyanovskiy
We actualized the content and/or weight coefficients of Russian diagnosis-related groups (DRG) for inpatient and day medical care payment. Costs of medicines were calculated using actual purchase prices. Thus the weight coefficients were recalculated for several DRG including admissions for antineoplastic therapy, chronic hepatitits C treatment and treatment with the use of genetically engineered biological drugs and selective immunosupressors. Three levels of patient treatment complexity coefficients were introduced to reimburse the cost of supportive therapy in oncology. Weight coefficients for payment for radionuclide therapy were recalculated. We actualized drug therapy regimens lists covered by DRG payment. It was made for antineoplastic therapy regimens and regimens of genetically engineered drugs and selective immunosuppressors. Charges for inpatient minimally invasive operations were increased via identifying 9 new groups. Payment approaches for immunization against respiratory syncytial infection were improved. The updated grouping algorithm of cases in oncology is described.